Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Descripción completa

Detalles Bibliográficos
Autores principales: Massimi, Davide, Barberio, Brigida, Bertani, Lorenzo, Costa, Francesco, Ferronato, Antonio, Facchin, Sonia, Cardin, Romilda, Cingolani, Linda, Casadei, Cesare, D’Incà, Renata, Zingone, Fabiana, Savarino, Edoardo Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239954/
https://www.ncbi.nlm.nih.gov/pubmed/34249147
http://dx.doi.org/10.1177/17562848211023384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239954/
https://www.ncbi.nlm.nih.gov/pubmed/34249147
http://dx.doi.org/10.1177/17562848211023384

Ejemplares similares